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geographical barriers while 63.5% and 58.5 % of them are in front of economic and 
waiting list barriers, respectively. More likely to face economic barriers in access are 
unemployed patients [coef.0.55; 95% CI (0.1, 1)] and patients with low income [-0.2; 
95% CI (-0.26,-0.13)] and lower educational level [-0.04; 95% CI (-0.08, 0)]. Women 
[0.22; 95% CI(0.02,0.42)], low-income patients [-0.13 ; 95% CI(-0.2, -0.06)], and patients 
with lower health status [-0.02 ; 95% CI(-0.02,-0.01)] are more likely to be in front 
of geographical barriers in access. Moreover, all occupational categories examined, 
demonstrate a statistically significant positive relationship with the probability of 
geographical barriers occurrence. In addition, unemployed patients [0.51; 95% CI 
(0.06, 1)], public or private sector employees [0.45; 95% CI (0.09, 0.81)] and low income 
patients [-0.086; 95% CI (-0.15, 0.02)] are more likely to deal with barriers attributed 
to waiting lists. ConClusions: Chronic patients face extensive barriers in access, 
which can mainly be explained by the fall of income, the rise of unemployment 
and the policy of decreasing the supply of certain health services in order to reduce 
health expenditure. If such barriers won’t be minimized inequalities will be enlarged 
and chronic patients’ health status will be worsened which might lead to increased 
future costs and adverse effects on health expenditures.
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objeCtives: From 2011, there are basic thresholds (λ 1= 24 x average monthly sal-
ary € / QALY and λ 2 = 35 x average monthly salary € / QALY) defined directly in the 
Slovak legislation reflecting the benefits displaced elsewhere in the Slovak health 
care system when funds are allocated to new medicines and medical devices. The 
objective of this study was to analyse the quality of submitted economic studies, 
related critical appraisals process and impacts of the new legislation on the access 
to medicines and medical devices. Methods: We created a working group to review 
previously submitted economic evaluations and related critical appraisals in order 
to identify potential technical and methodological problems. The working group 
scrutinized previous submissions and critical appraisals, concerning to chosen ATC 
groups of drugs and groups of medical devices, published between June 2012 and 
June 2013 at the webside of MoH. Results: Pharmacoeconomic evaluations of drugs 
and medical devices within decision making process concerning to reimbursement 
are mandatory but the quality of studies are very often rather poor. The concept “the 
QALY is a tool not a rule” was slightly modified in Slovakia. Our analysis shows that 
implicit thresholds included into the Slovak legislation have influenced decision-
making process concerning to drugs and medical devices. In the defined time period 
4 drugs exceeded the basic thresholds described in the Slovak legislation, however 
108 drugs and medical devices were refused to include into the reimbursement 
list, because of the poor quality of provided pharmacoeconomic studies from the 
side of applicants. ConClusions: The transparent method of HTA can improve 
the consistency of reimbursement decisions making related to drugs and medical 
devices in Slovakia. However significant improvements in the quality of submitted 
pharmacoeconomic dossiers have to be the first step towards the better access to 
drugs and medical devices for the Slovak patients.
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objeCtives: Developed countries have embraced the purchaser-provider split as 
a mechanism to improve health resource allocation and outcomes. With the emer-
gence of Clinical Commissioning Groups (CCGs) as both buyers and providers of 
health services a hybrid purchaser-provider model is being explored. This research 
explored the opportunities and challenges of this model and analysed the impli-
cations for NHS England and Europe. Methods: Eighty influential regional and 
national payers involved in the NHS England reforms took part in 1-hour tele-depth 
interviews to better understand the changes and uncertainties before the reforms 
were implemented. This research was re-visited three months post implementa-
tion in an advisory board setting to externally validate our findings and identify 
case studies for further analysis. Results: NHS payers stated that they were still 
‘broadly optimistic’ about the re-allocation of purchaser responsibilities to CCGs. 
One case study illustrated that greater clinician involvement provided opportuni-
ties to redesign services like respiratory care and allocate funding more efficiently 
between acute and primary care. Initial success stories include the creation of 
primary care diabetes clinics and Pharma-NHS local partnerships to help reduce 
hospital activity. Within the advisory board, payers voiced concerns with this hybrid 
model. Questions raised from the meeting included: 1) How do we equip GP commis-
sioners with the right skill set to draft and negotiate hospital contracts? 2) How can 
we help GP commissioners and GP providers to help minimise potential conflicts of 
interest? ConClusions: The purchaser-provider model implemented in England 
presents a new way to tackle reduced financial budgets and need to improve health 
outcomes. The results of this research suggest that the purchaser-provider model 
has the potential to make a difference for patient care. A number of challenges 
appear to still be present and it will be important to address these in order for the 
UK and other countries to further explore its benefits.
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Drug Interaction Facts. Results: A highly significant difference was observed 
between the prevalence of pDDIs in prescriptions from hospital (45%; 180 out of 
400 prescriptions with at least 1 pDDI) and community pharmacies (29.25%; 117 
out of 400 prescriptions with atleast 1 pDDI). On the whole, out of total 543 pDDIs 
(hospital = 337; community = 206) majority of them were of delayed onset (hospital 
= 50.44%, community = 44.66%), moderate severity (hospital = 57.87%, community 
= 42.72%), suspected type (hospital = 27.6%) and possible documentation (com-
munity = 14.08%). Most of the prescriptions (hospital = 80%; community = 83%) 
contained 2-4 medicines. The interacting combinations such as aspirin-clopidogrel 
omeprazole-clopidogrel and digoxin-furosemide (in hospital); isoniazid-rifampin 
and tramadol-escitalopram were found to be frequently involved in major inter-
actions. The findings showed that cardiovascular drugs were involved in most of 
the rapid pDDIs (in hospital = 32.46%; in community = 33.33%) and respiratory 
system drugs were associated with majority of established documented pDDIs (in 
hospital = 16.67%; in community = 42.86%). ConClusions: Drug-drug interac-
tions in prescription medicines were observed in high percentage both in hospitals 
and community pharmacies. Clinical practices must be standardized as rational 
prescribing practices.
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objeCtives: To examine access of migrants in health care services, their unmet 
health needs, and the factors associated with these. Methods: A cross-sectional 
pilot study was conducted from January to May 2013. The study population consisted 
of 231 recent immigrants living in Greece. A questionnaire was developed including 
information about demographics, health status, difficulties in health services access 
etc. Statistical analysis included Pearson’s x2 test, x2test for trend, student’s t-test, 
analysis of variance and Pearson’s correlation coefficient. Results: Almost half of the 
participants (n= 115, 49.7%) used public health services in the last 12 months in Greece. 
Among them, 56.8% (n= 131) used emergency department services. A considerable 
proportion of the participants (n= 144,62.3%), during the last year, needed at least one 
time to use health services but they could not afford it. The most important reasons 
for that were high cost of health care (n= 80, 34.5%) and the long waiting lists (n= 29, 
12.6%). More than half of the participants (n= 122, 52.9%) reported that they had major 
difficulties in accessing health services. Increased family monthly income was associ-
ated with decreased difficulties in access in health services (x2 test for trend= 32.1, 
p< 0.001). The use of preventive services has been limited since more than 60% of 
the women 40+ reported not having conducted a pap test or a mammography, while 
more than 30% of the respondents were not subjected to a blood test or a cholesterol 
examination. ConClusions: Barriers to health services access for migrants may 
lead to decreased use of health services, especially primary, and thus lead to increased 
hospitalizations and higher cost in the longer-run. Formulation of policies to improve 
access and use of health care services are necessary.
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objeCtives: Cost effectiveness analyses play a critical role in determining coverage 
of novel drugs and devices. Increasingly, payers are demanding subgroup analyses 
to determine indications which would be covered by the national health system or 
insurance agency. Methods: To understand and review trends in the use of subgroup 
cost effectiveness analysis, we analyzed NICE HTAs for products approved between 
2011-2012. Manufacturer submissions for CEA were compared to final review and 
decision by HTA agency. Analogs were identified and case studies were developed 
to further understand the use of subgroup analyses and cost effectiveness mod-
els. Results: Decisions made by NICE in 2011-2012 show increasing trends towards 
the use of subgroup analysis for determining indications for coverage by national 
payer bodies. Between 2011-2012, 80% of the assessments included subgroup analy-
ses. Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same subgroups 
showed a large variation (1X-3X fold difference) compared to ICER values estimated 
by manufacturers. Selected case studies highlighted that for several products, NICE is 
recommending treatments only for subgroups whose ICER values are within the cost 
effectiveness threshold. ConClusions: New products need robust broader popula-
tion and subgroup analyses for insurance coverage.
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objeCtives: To explore the magnitude of certain access barriers to physician ser-
vices that chronic patients are in front of as well as which patients are more vul-
nerable to such restrictions. Methods: A cross-sectional study was conducted in 
1600 chronic patients suffering from diabetes, hypertension, COPD and Alzheimer. 
Logistic regression analysis was carried out in order to explore the factors related 
to economic and geographical barriers in access, as well as the determinants of 
barriers imposed by waiting lists. Results: A total of 25% of chronic patients face 
